Insight on Therapy Area in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Women's Health Market Strategies - Opportunities remain in this overlooked therapy area

This report aims to explore the opportunities and challenges in the women’s health sector. Market access is evaluated and includes analysis of drug sales, key players, regulatory trends, licensing deals, unmet needs, and marketing strategies.

Published By Datamonitor
12 Oct 2011 $2800
Buy
Report
Report

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.

Published By Datamonitor
18 May 2011 $1520
Buy
Report
Report

Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success

Full analysis of the future urinary incontinence market. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) for key marketed brands, generics, and pipeline products.

Published By Datamonitor
15 Dec 2010 $6400
Buy
Report
Report

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.

Published By Datamonitor
22 Dec 2010 $15200
Buy
Report
Report

Forecast Insight: Antidiabetics - UPDATE 2: Bydureon delay boosts Victoza sales, but the status quo remains largely unchanged. Avandia sales restrictions lead to patient switching, opportunities for multiple drug classes.

Analysis of the competitive landscape and the recent changes in antidiabetics across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunities available to novel agent classes.

Published By Datamonitor
22 Oct 2010 $15200
Buy
Report
Report

Prescribing Influences: Bipolar Disorders - Improved control of bipolar depression persists as greatest unmet need

This report analyzes the unmet needs of bipolar disorders treatment and the attributes of drugs that influence the prescribing decisions made by psychiatrists across the seven major markets.

Published By Datamonitor
30 Jul 2012 $2800
Buy
Report
Report

Innovations in Ophthalmic Devices – Anterior Segment

Innovations in anterior segment ophthalmic devices will grow the market for presbyopia treatments and improve visual outcomes. They will also provide earlier diagnoses of dry eye and offer benefits in refractive and cataract surgery.

Published By Datamonitor
18 Oct 2012 $2800
Buy
Report
Report

R&D Trends: Chronic Nociceptive Pain – Abundance fails to be matched by innovation

Review of key trends in the chronic nociceptive pain pipeline. Includes a detailed analysis of clinical trial design, target product profile, innovative early-stage approaches and future treatment developments.

Published By Datamonitor
21 Sep 2012 $2800
Buy
Report
Report

Product Profiles: Non-Insulin Antidiabetics – Options abound as the SGLT-2 class prepares for market entry

Datamonitor profiles leading, currently marketed non-insulin brands as well as pipeline products launching in the near future. Coverage: the US, Japan, France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
14 Aug 2012 $4800
Buy
Report
Report

Market and Product Forecasts: HER2-Negative/Hormone Receptor-Positive Breast Cancer - Patent expiries and novel drugs shape the market in the next decade

This report and accompanying deliverable provides forecasts for HER2-/HR+ breast cancer drugs in the seven major markets from 2011-20. Including in-depth analysis of the market in individual countries and molecule dynamics of the key therapies.

Published By Datamonitor
19 Jul 2012 $6400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.